담관암(담도암) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Cholangiocarcinoma (Bile Duct Cancer) Emerging Therapy and TPP Insights

Thelansis's "Cholangiocarcinoma (Bile Duct Cancer) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Cholangiocarcinoma (Bile Duct Cancer) Overview

Cholangiocarcinoma is a malignancy arising from biliary epithelial cells, classified as intrahepatic, perihilar, or distal, driven by chronic biliary inflammation, FGFR2 fusions, IDH1/2 mutations, and KRAS alterations promoting oncogenic transformation. It presents with progressive obstructive jaundice, pruritus, weight loss, and abdominal pain, with perihilar tumors causing early biliary obstruction. Diagnosis integrates MRI/MRCP, CA19-9, and tissue biopsy with molecular profiling; vascular involvement and metastatic spread define resectability. Surgical resection remains the only curative option; gemcitabine-cisplatin with durvalumab is the standard first-line systemic regimen. FGFR2 and IDH1 inhibitors provide targeted options in molecularly selected patients. Biliary drainage optimizes symptom control. Early palliative integration and goals-of-care planning are essential given poor overall prognosis.

Key Highlights

• In Germany, diagnosed cholangiocarcinoma cases are projected to increase from approximately 4,388 in 2025 to 4,612 by 2035.
• CCA remains an aggressive biliary tract malignancy associated with poor prognosis and limited survival.
• Late-stage diagnosis continues to contribute to significant disease burden and mortality.
• Molecular profiling is increasingly enabling targeted treatment approaches.
• FGFR inhibitors, IDH inhibitors, and immunotherapies are expanding therapeutic options.

Market Overview

• The Germany cholangiocarcinoma market is projected to grow from approximately $200 MN to $680 MN by 2035.
• Market growth is supported by:
• Increasing adoption of targeted therapies and immunotherapy
• Growing use of biomarker-driven treatment strategies
• Market value growth is driven by premium oncology therapies and expanding eligible patient populations.
• Future growth will depend on precision oncology advancements and next-generation targeted treatments.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Genfit
• RedHill Biopharma Limited
• Eisai Co., Ltd.
• Incyte Corporation
• Servier
• Virogin Biotech Ltd.
• 3D Medicines (Beijing) Co., Ltd.
• TransThera Sciences (Nanjing), Inc.
• Taiho Oncology, Inc.
• Boehringer Ingelheim
• Verismo Therapeutics
• Hutchmed
• Medivir
• Eli Lilly and Company
• Bold Therapeutics, Inc.
• Elevar Therapeutics
• Rigel Pharmaceuticals
• Compass Therapeutics
• Toray Industries, Inc.
• MacroGenics
• Cogent Biosciences, Inc.
• Pheast Therapeutics
• Leap Therapeutics, Inc.
• Seagen, a wholly owned subsidiary of Pfizer
• SOFIE
• TCR2 Therapeutics
• Alentis Therapeutics AG
• Elicio Therapeutics
• Arbele Pty Ltd.
• Apollo Therapeutics Ltd.
• Context Therapeutics Inc.
• Merck Sharp & Dohme LLC
• Celldex Therapeutics
• Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)